Overview

“Phase 3 Randomized, Open-Label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2-overexpressing PD-L1 TPS <50% Non-Squamous Non-small Cell Lung Cancer (DESTINY-Lung06)”

This is a Phase 3 clinical trial involving multiple centers. It's designed to evaluate how well trastuzumab deruxtecan (T-DXd; Enhertu) works with pembrolizumab compared to standard chemotherapy with pembrolizumab. The study focuses on patients who haven't received treatment before for advanced non-small cell lung cancer (NSCLC) that has certain characteristics, specifically HER2 overexpression and low levels of PD-L1. The main goal is to see which combination—T-DXd with pembrolizumab or chemotherapy with pembrolizumab—works better as the first treatment option for these patients.